Vanguard Medica shares fall
SHARES IN Vanguard Medica fell 10p to 320p after it said it intended to stop developing two psoriasis treatments, the compounds, VML 295 and VML 262. Vanguard said its decision followed a re-evaluation of the commercial potential of these compounds on completion of phase two studies.
Register for free to continue reading
Registration is a free and easy way to support our truly independent journalism
By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists
Already have an account? sign in
Join our new commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies